Loading company…
Xi'an-based biotech developing CAR-T cell therapies for cancer, with GMP production, gene editing and antibody screening services.
Based in Xi'an, China and established in 2016, Xian Yufan Biotechnology focuses on Chimeric Antigen Receptor T-Cell immunotherapy (CAR-T) for cancer treatment. Its services include CAR-T cell GMP production, CRISPR/Cas9 gene editing for immune cells, phage antibody library development and phage display technology. The company earns revenue from its CAR-T therapies, antibody screening platforms and contract research services for biopharmaceutical companies, research institutions and clinical facilities. Stage: Seed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in